Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.


Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.

Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V.

Br J Cancer. 2018 Feb 20. doi: 10.1038/bjc.2017.480. [Epub ahead of print]


Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer.

Tang C, Hobbs B, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D, Chang JY, Hong DS, Welsh JW, Sepesi B, Court L, Wistuba II, Koay EJ.

Sci Rep. 2018 Jan 31;8(1):1922. doi: 10.1038/s41598-018-20471-5.


Evaluation of nausea and vomiting in pregnancy using the Pregnancy-Unique Quantification of Emesis and Nausea scale in Korea.

Choi HJ, Bae YJ, Choi JS, Ahn HK, An HS, Hong DS, Yun JS, Han JY.

Obstet Gynecol Sci. 2018 Jan;61(1):30-37. doi: 10.5468/ogs.2018.61.1.30. Epub 2017 Dec 14.


Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.

Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, Ai M, Reilley MJ, Sebastian MM, Hong DS, Curran MA.

Clin Cancer Res. 2018 Mar 1;24(5):1138-1151. doi: 10.1158/1078-0432.CCR-17-1847. Epub 2018 Jan 4.


Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V.

J Immunother Cancer. 2017 Dec 19;5(1):100. doi: 10.1186/s40425-017-0301-y.


Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers.

Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F.

Mol Cancer Ther. 2017 Dec 13. pii: molcanther.0673.2017. doi: 10.1158/1535-7163.MCT-17-0673. [Epub ahead of print]


Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.

Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V.

Sci Rep. 2017 Nov 21;7(1):15963. doi: 10.1038/s41598-017-13114-8.


Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A.

Invest New Drugs. 2017 Nov 21. doi: 10.1007/s10637-017-0534-0. [Epub ahead of print]


Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.

Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah V.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx094.


Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002. Epub 2017 Sep 8.


Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.

Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A.

Invest New Drugs. 2017 Oct 27. doi: 10.1007/s10637-017-0524-2. [Epub ahead of print]


Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.

Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F.

Clin Cancer Res. 2018 Jan 1;24(1):181-188. doi: 10.1158/1078-0432.CCR-17-2007. Epub 2017 Oct 19.


Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.

Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS.

Invest New Drugs. 2017 Oct 19. doi: 10.1007/s10637-017-0513-5. [Epub ahead of print]


X-Chromosome Effects on Attention Networks: Insights from Imaging Resting-State Networks in Turner Syndrome.

Green T, Saggar M, Ishak A, Hong DS, Reiss AL.

Cereb Cortex. 2017 Jul 18:1-8. doi: 10.1093/cercor/bhx188. [Epub ahead of print]


Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.

Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS.

Oncotarget. 2017 May 5;8(35):58709-58727. doi: 10.18632/oncotarget.17634. eCollection 2017 Aug 29.


Near-Fatal Gastrointestinal Hemorrhage in a Child with Medulloblastoma on High Dose Dexamethasone.

Yecies D, Tawfik D, Damman J, Thorson C, Hong DS, Grant GA, Bensen R, Damian M.

Cureus. 2017 Jul 7;9(7):e1442. doi: 10.7759/cureus.1442.


Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells.

Schroeder RD, Choi W, Hong DS, McConkey DJ.

Oncotarget. 2017 Jun 7;8(31):51675-51687. doi: 10.18632/oncotarget.18386. eCollection 2017 Aug 1.


Here/In This Issue and There/Abstract Thinking: The Growing, and Changing, Landscape of Child and Adolescent Mental Healthcare Delivery.

Hong DS.

J Am Acad Child Adolesc Psychiatry. 2017 Sep;56(9):719-720. doi: 10.1016/j.jaac.2017.07.007. No abstract available.


Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape.

Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS.

Oncoscience. 2017 Jun 23;4(5-6):47-56. doi: 10.18632/oncoscience.352. eCollection 2017 May.


Molecular characterization of breast cancer CTCs associated with brain metastasis.

Boral D, Vishnoi M, Liu HN, Yin W, Sprouse ML, Scamardo A, Hong DS, Tan TZ, Thiery JP, Chang JC, Marchetti D.

Nat Commun. 2017 Aug 4;8(1):196. doi: 10.1038/s41467-017-00196-1.


Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS.

Clin Cancer Res. 2017 Jul 20. doi: 10.1158/1078-0432.CCR-16-3027. [Epub ahead of print]


Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients.

Oh SY, Shin SW, Koh SJ, Bae SB, Chang H, Kim JH, Kim HJ, Hong YS, Park KU, Park J, Lee KH, Lee NR, Lee JL, Jang JS, Hong DS, Lee SS, Baek SK, Choi DR, Chung J, Oh SC, Han HS, Yun HJ, Sym SJ, Yoon SY, Choi IS, Shim BY, Kang SY, Kim SR, Kim HJ.

Support Care Cancer. 2017 Dec;25(12):3759-3767. doi: 10.1007/s00520-017-3806-5. Epub 2017 Jul 8.


Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

Sundar R, Hong DS, Kopetz S, Yap TA.

Cancer Discov. 2017 Jun;7(6):558-560. doi: 10.1158/2159-8290.CD-17-0087.


Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.

Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS.

Clin Cancer Res. 2017 Sep 15;23(18):5648-5656. doi: 10.1158/1078-0432.CCR-17-0291. Epub 2017 May 23.


Linking ADHD to the Neural Circuitry of Attention.

Mueller A, Hong DS, Shepard S, Moore T.

Trends Cogn Sci. 2017 Jun;21(6):474-488. doi: 10.1016/j.tics.2017.03.009. Epub 2017 May 5. Review.


Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.

Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS.

J Immunother Cancer. 2017 Apr 18;5:35. doi: 10.1186/s40425-017-0238-1. eCollection 2017.


Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.

Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V.

Oncotarget. 2017 Jun 13;8(24):39254-39267. doi: 10.18632/oncotarget.16845.


First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS.

JCI Insight. 2017 Apr 20;2(8). pii: 90380. doi: 10.1172/jci.insight.90380. [Epub ahead of print]


Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers.

Cox VL, Bhosale P, Varadhachary GR, Wagner-Bartak N, Glitza IC, Gold KA, Atkins JT, Soliman PT, Hong DS, Qayyum A.

Radiology. 2017 May;283(2):314-340. doi: 10.1148/radiol.2017152224. Review.


Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs.

Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, Razak ARA, Hong DS.

Clin Cancer Res. 2017 Aug 1;23(15):4020-4026. doi: 10.1158/1078-0432.CCR-16-2354. Epub 2017 Apr 4.


A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.

Tolcher AW, Berlin JD, Cosaert J, Kauh J, Chan E, Piha-Paul SA, Amaya A, Tang S, Driscoll K, Kimbung R, Kambhampati SR, Gueorguieva I, Hong DS.

Cancer Chemother Pharmacol. 2017 Apr;79(4):673-680. doi: 10.1007/s00280-017-3245-5. Epub 2017 Mar 9.


Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.

Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ.

Clin Cancer Res. 2017 Mar 15;23(6):1414-1421. doi: 10.1158/1078-0432.CCR-16-2439. Epub 2017 Mar 8.


Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.

Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DS.

J Clin Oncol. 2017 Apr 20;35(12):1304-1311. doi: 10.1200/JCO.2016.70.7117. Epub 2017 Feb 27.


Here/In This Issue and There/Abstract Thinking: The First Year: Incorporating Maternal Mental Health Into Child Psychiatric Practice.

Hong DS.

J Am Acad Child Adolesc Psychiatry. 2017 Mar;56(3):183-184. doi: 10.1016/j.jaac.2017.01.001. No abstract available.


Targeting TRK family proteins in cancer.

Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.

Pharmacol Ther. 2017 May;173:58-66. doi: 10.1016/j.pharmthera.2017.02.006. Epub 2017 Feb 4. Review.


Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience.

Yoo SH, Koh Y, Kim DY, Lee JH, Lee JH, Lee KH, Yoon SS, Park S, Park SK, Hong DS, Yi HG, Kim CS, Jang JE, Cheong JW, Moon J, Min YH, Sohn SK, Kim I; Korean Society of Blood and Marrow Transplantation.

Ann Hematol. 2017 Apr;96(4):605-615. doi: 10.1007/s00277-017-2919-8. Epub 2017 Jan 16.


Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.

Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, Tsimberidou AM, Piha-Paul SA, Wheler JJ, Zinner RG, Naing A, Hong DS, Karp DD, Cabrilo G, Kopetz ES, Subbiah V, Luthra R, Kee BK, Eng C, Morris VK, Karlin-Neumann GA, Meric-Bernstam F.

Ann Oncol. 2017 Mar 1;28(3):642-650. doi: 10.1093/annonc/mdw670.


Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.

Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S, Hong DS.

Invest New Drugs. 2017 Apr;35(2):180-188. doi: 10.1007/s10637-016-0407-y. Epub 2016 Dec 5.


Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual.

Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1407-1413. doi: 10.1158/1078-0432.CCR-16-1936. Epub 2016 Nov 16.


A Case of Chronic Myeloid Leukemia With Rare Variant ETV6/ABL1 Rearrangement.

Choi SI, Jang MA, Jeong WJ, Jeon BR, Lee YW, Shin HB, Hong DS, Lee YK.

Ann Lab Med. 2017 Jan;37(1):77-80. doi: 10.3343/alm.2017.37.1.77. No abstract available.


Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.

Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V.

Oncology. 2017;92(1):14-20. doi: 10.1159/000449505. Epub 2016 Nov 2.


Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20.


Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.

Kim CK, Han DH, Ji YS, Lee MS, Min CW, Park SK, Kim SH, Yun J, Kim HJ, Kim KH, Lee KT, Won JH, Hong DS, Kim HK.

Leuk Res. 2016 Nov;50:21-28. doi: 10.1016/j.leukres.2016.08.012. Epub 2016 Sep 5.


Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.

George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS.

Cancer. 2016 Nov 15;122(21):3401-3409. doi: 10.1002/cncr.30182. Epub 2016 Jul 14.


Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.

Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS.

Sci Rep. 2016 Oct 17;6:35448. doi: 10.1038/srep35448.


Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.

Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM.

Int J Cancer. 2017 Jan 1;140(1):208-215. doi: 10.1002/ijc.30417. Epub 2016 Oct 17.


Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S.

Cancer Discov. 2016 Dec;6(12):1352-1365. Epub 2016 Oct 11.


RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

Barata P, Sood AK, Hong DS.

Cancer Treat Rev. 2016 Nov;50:35-47. doi: 10.1016/j.ctrv.2016.08.004. Epub 2016 Aug 28. Review.


Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.

Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F.

Oncotarget. 2016 Oct 11;7(41):67521-67531. doi: 10.18632/oncotarget.11750.

Supplemental Content

Support Center